All stock lists
Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
Healthcare · Biotechnology
3.02-0.06 (-1.95%)
Insider Score
––Not scored
ARDX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Financial Health Score
Fair
From ARDX’s reported statements · Q2 2026 (trailing 12 months)
Profitability4 / 20
Loses money on what it sells.
- Revenue
- $450.9M
- Net income
- -$55.7M
- Net margin
- -12.4%
Leverage3 / 20
Heavily indebted for what it earns.
- Total debt
- $256.2M
- Cash
- $97.2M
- Debt / equity
- 1.72
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $441.9M
- Current liabilities
- $132.2M
- Current ratio
- 3.34
Cash generation9 / 20
Roughly cash-neutral.
- Operating cash flow
- -$17.3M
- Free cash flow
- -$17.9M
- FCF margin
- -4.0%
Dilution & runway17 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 248.1M
- Share growth (1y)
- 3.4%
- Cash runway
- 67 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ARDX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 120.88 M | 94.47 M | 125.22 M | 110.33 M | 97.66 M |
| Revenue Growth (YoY) | 23.77 % | — | — | — | — |
| Cost of Revenue | 5.76 M | 4.81 M | 10.85 M | 3.98 M | 12.40 M |
| Gross Profit | 115.12 M | 89.66 M | 114.37 M | 106.35 M | 85.26 M |
| SG&A Expense | 101.44 M | 102.27 M | 86.41 M | 83.61 M | 83.99 M |
| R&D Expense | 26.10 M | 20.19 M | 22.86 M | 18.07 M | 15.67 M |
| Operating Expenses | 127.54 M | 122.45 M | 109.27 M | 101.68 M | 99.65 M |
| Operating Income | -12.43 M | -32.79 M | 5.10 M | 4.67 M | -14.39 M |
| Pretax Income | -16.61 M | -37.60 M | -400.00 K | -867.00 K | -19.08 M |
| Tax Provision | 110.00 K | 8.00 K | 7.00 K | 102.00 K | 1.00 K |
| Net Income | -16.72 M | -37.60 M | -407.00 K | -969.00 K | -19.08 M |
| EPS (Basic) | -0.07 | -0.15 | 0.00 | 0.00 | -0.08 |
| EPS (Diluted) | -0.07 | -0.15 | 0.00 | 0.00 | -0.08 |
| Shares Outstanding | 248.07 M | 245.86 M | 243.61 M | 241.91 M | 239.93 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.